Netobimin is an antiparasitic drug used to treat infections caused by certain types of intestinal worms. It is an imidazothiazole derivative, characterized by its broad-spectrum activity against various parasites, including cestodes (tapeworms) and nematodes (roundworms) that affect both humans and animals. Netobimin is effective in treating infections caused by parasites like Taenia saginata, Taenia solium, Echinococcus granulosus, and Diphyllobothrium latum. It works by inhibiting the parasite's energy production, leading to their death. The drug is administered orally and is generally well-tolerated, with few side effects. Its importance lies in its efficacy against a wide range of parasites, making it a valuable tool for both human and veterinary medicine. Extensive research continues to explore its potential against other parasitic infections and its potential to be developed into more potent and specific antiparasitic drugs. '
netobimin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71449 |
| CHEMBL ID | 2105153 |
| SCHEMBL ID | 124507 |
| MeSH ID | M0142106 |
| Synonym |
|---|
| AKOS015843263 |
| methyl (n'-(2-nitro-5-(propylthio)phenyl)-n-(2-sulfoethyl)amidino)carbamate |
| netobiminum [latin] |
| sch 32481 |
| hapasil |
| ethanesulfonic acid, 2-((((methoxycarbonyl)amino)((2-nitro-5-(propylthio)phenyl)imino)methyl)amino)- |
| netobimina [spanish] |
| 2-(3-methoxycarbonyl-2-(2-nitro-5-propylthiophenyl)guanidino)ethansulfonsaeure |
| netobimine [french] |
| netobimin |
| D05149 |
| 88255-01-0 |
| netobimin (usan/inn) |
| MIXCOM1_000186 |
| MAYBRIDGE1_000098 |
| SR-01000631189-1 |
| 2-[[(methoxycarbonylamino)-(2-nitro-5-propylsulfanylanilino)methylidene]amino]ethanesulfonic acid |
| FT-0653829 |
| (z)-2-((((methoxycarbonyl)amino)((2-nitro-5-(propylthio)phenyl)amino)methylene)amino)ethane-1-sulfonic acid |
| A842510 |
| CHEMBL2105153 |
| sch-32481 |
| CCG-41089 |
| netobiminum |
| unii-u30c54n3mu |
| netobimina |
| netobimin [usan:inn:ban] |
| u30c54n3mu , |
| netobimine |
| BCP9000985 |
| AKOS015896440 |
| netobimin [mi] |
| netobimin [usan] |
| netobimin [mart.] |
| methyl (n'-(2-nitro-5-(propylthio)phenyl)-n-(2-sulfoethyl)amidino)carbamate. |
| netobimin [inn] |
| SCHEMBL124507 |
| MLS006012015 |
| smr004703555 |
| J-523576 |
| DTXSID20236925 |
| (e)-2-(3-(methoxycarbonyl)-2-(2-nitro-5-(propylthio)phenyl)guanidino)ethanesulfonic acid |
| Q19297153 |
| BCP29587 |
| tobatin pound>>sch 32481 |
| ethanesulfonic acid,2-[[[(methoxycarbonyl)amino][[2-nitro-5-(propylthio)phenyl]amino]methylene]amino]- |
Netobimin (NTB) is a prodrug of albendazole (ABZ) and is used as a broad-spectrum anthelmintic.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Netobimin (NTB) is a prodrug of albendazole (ABZ) and is used as a broad-spectrum anthelmintic both in human and veterinary medicine. " | ( Developmental toxicity in rat fetuses exposed to the benzimidazole netobimin. Arboix, M; Canut, L; Carretero, A; Cristofol, C; Navarro, M; Pérez-Aparicio, FJ; Ruberte, J, ) | 1.81 |
A comparison of the pharmacokinetic profiles of netobimin (NTB), albendazole sulfoxide (ABZSO) and ABZSO2 was performed in gerbils with intra-abdominal hydatidosis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "In a 4 x 4 crossover-design study, pharmacokinetic variables of 2 injectable formulations of netobimin (trisamine salt solution and zwitterion suspension) were compared after SC administration in calves at dosage of 12." | ( Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. Lanusse, CE; Prichard, RK; Ranjan, S, 1990) | 0.73 |
| " No statistically significant differences were found between the pharmacokinetic parameters of albendazole suphoxide (ABZSO) and albendazole sulphone (ABZSO2) among the three groups of ewes." | ( Comparative pharmacokinetics of netobimin metabolites in pregnant ewes. Arboix, M; Carretero, A; Cristòfol, C; Franquelo, C; Navarro, M; Ruberte, J, ) | 0.41 |
| "A comparison of the pharmacokinetic profiles of netobimin (NTB), albendazole sulfoxide (ABZSO) and albendazole sulfone (ABZSO2) was performed in gerbils (Meriones unguiculatus) with intra-abdominal hydatidosis and in healthy gerbils." | ( Pharmacokinetics of netobimin and microsomal metabolism of albendazole in infected gerbils with Echinococcus granulosus. Alvarez-de-Felipe, AI; García-Llamazares, JL; Larrode-Pellicer, O; Merino-Pelaez, G; Prieto-Fernández, JG; Redondo-Cardeña, PA, 2001) | 0.89 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The effects of methimazole (MTZ), metyrapone (MTP) and quinine (QNE) on the pharmacokinetics and bioavailability of parenterally administered netobimin (NTB) and its major metabolites, albendazole sulphoxide (ABZSO) and albendazole sulphone (ABZSO2), were studied in sheep." | ( Enhancement of the plasma concentration of albendazole sulphoxide in sheep following coadministration of parenteral netobimin and liver oxidase inhibitors. Lanusse, CE; Prichard, RK, 1991) | 0.69 |
| "05) in the bioavailability of any of the anthelmintics tested between parasitized and non-parasitized animals." | ( Effect of parasitism with Nematodirus battus on the pharmacokinetics of levamisole, ivermectin and netobimin. Coop, RL; Jackson, E; Jackson, F; McKellar, QA; Scott, E, 1991) | 0.5 |
| " The corrected metabolite AUCs following NTB were, however, significantly lower than those following ABSO administration in 1-month-old lambs, suggesting that immature metabolic processes in these animals contributed to the lower relative bioavailability of NTB in this age group." | ( The pharmacokinetics of albendazole metabolites following administration of albendazole, albendazole sulfoxide and netobimin to one-month- and eight-month-old sheep. Coop, RL; Jackson, F; McKellar, QA, 1995) | 0.5 |
| " Because benzimidazole anthelmintic drugs are generally administered orally, the ruminal flora play an important role in the bioavailability of these drugs." | ( Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen. Arboix, M; Calsamiglia, S; Capece, BP; Castells, G; Cristòfol, C, 2001) | 0.56 |
Netobimin was given as an oral drench to Merino sheep. The AUC0-infinity of albendazole sulphoxide was significantly increased (75.1 mg kg-1) at the lower dosage.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Egg counts and faecal cultures were taken before dosing on the day of treatment and seven days later when all animals were necropsied and the nematodes were collected from the abomasa and counted." | ( Haemonchus contortus resistance to ivermectin and netobimin in Brazilian sheep. Berne, ME; Cavalcante, AC; Costa, CA; Vieira, LS, 1992) | 0.54 |
| " One group was left as a non-treated control (T0), the second was dosed 15 days before parturition (T1), and the remaining group dosed both at 15 days before and 15 days after lambing (T2)." | ( Effect of treatment with netobimin on milk production of sheep. García Pérez, AL; Juste Jordán, RA, 1991) | 0.58 |
| " The fecal egg counts were reduced by 44 to 79% depending on dosage on postdrenching day 18; the remaining worms were Trichostrongylus colubriformis." | ( Efficacy of netobimin against Muellerius capillaris and resistant strain of digestive tract strongyles in dairy goats. Cabaret, J, 1991) | 0.66 |
| "In a 4 x 4 crossover-design study, pharmacokinetic variables of 2 injectable formulations of netobimin (trisamine salt solution and zwitterion suspension) were compared after SC administration in calves at dosage of 12." | ( Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. Lanusse, CE; Prichard, RK; Ranjan, S, 1990) | 0.73 |
| "5 and 20 mg kg-1 dosage groups (given the netobimin as an oral drench)." | ( The anthelmintic efficacy of netobimin against naturally acquired gastrointestinal nematodes in sheep. Dawley, SW; Hoberg, EP; Richards, LS; Schons, DJ; Zimmerman, GL, 1987) | 0.83 |
| " Non-pregnant ewes and ewes in the first and last third of pregnancy were dosed orally with 20 mg kg bodyweight of NTB." | ( Comparative pharmacokinetics of netobimin metabolites in pregnant ewes. Arboix, M; Carretero, A; Cristòfol, C; Franquelo, C; Navarro, M; Ruberte, J, ) | 0.41 |
| "1 mg kg-1) to Merino sheep, the AUC0-infinity of albendazole sulphoxide at the lower dosage of netobimin, was significantly increased (75." | ( Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. Alvarez, AI; Garcia, JL; Larrodé, OM; Merino, G; Prieto, JG; Redondo, PA, 1999) | 0.78 |
| " Within each period two fermenters per treatment were immediately dosed with 104 mg of netobimin, 52 mg of albendazole, or 39 mg of albendazole sulfoxide." | ( Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen. Arboix, M; Calsamiglia, S; Capece, BP; Castells, G; Cristòfol, C, 2001) | 0.78 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (18.75) | 18.7374 |
| 1990's | 24 (50.00) | 18.2507 |
| 2000's | 12 (25.00) | 29.6817 |
| 2010's | 2 (4.17) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.49) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (1.79%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 55 (98.21%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||